Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 10/20 | 0.42 |
| ▸ | CDK1 | P06493 | 10/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 10/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 10/20 | 0.42 |
| ▸ | GSK3B | P49841 | 9/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14730759 | 0.92 | LMNA (0.60) | LMNAMAPTALDH1A1MAPK1MAPKAPK2 | |
| SCHEMBL17172718 | 0.85 | LMNA (0.49) | LMNAMAPTALDH1A1MAPK1MAPKAPK2 | |
| SCHEMBL14731470 | 0.84 | MAPKAPK2 (0.44) | LMNAMAPTALDH1A1MAPK1MAPKAPK2 | |
| SCHEMBL14731462 | 0.82 | LMNA (0.55) | LMNAMAPTALDH1A1MAPK1MAPKAPK2 | |
| SCHEMBL14731473 | 0.75 | MAPKAPK2 (0.42) | LMNAMAPTALDH1A1MAPK1MAPKAPK2 | |
| SCHEMBL14730680 | 0.75 | GSK3B (0.46) | MAPTALDH1A1MAPKAPK2HSD17B10CCNB2 | |
| SCHEMBL16248397 | 0.73 | LMNA (0.50) | LMNAMAPTALDH1A1MAPK1MAPKAPK2 | |
| SCHEMBL14730719 | 0.73 | KDM4E (0.44) | LMNAMAPTALDH1A1MAPK1MAPKAPK2 | |
| SCHEMBL4156981 | 0.73 | LMNA (0.94) | LMNAMAPTALDH1A1MAPK1HSD17B10 | |
| SCHEMBL31721163 | 0.73 | LMNA (1.00) | LMNAMAPTALDH1A1MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340548-B2 | Substituted pyrazolo[3,4-a]carbazoles as hepatitis C inhibitors | Boehringer Ingehleim International GmbH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340548-B2 | Substituted pyrazolo[3,4-a]carbazoles as hepatitis C inhibitors | Boehringer Ingehleim International GmbH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20150291592-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150291592-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| WO-2013026163-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | HCCS, C1R, HAVCR2 | LMNA 1026/4885MAPT 4686/4885ALDH1A1 1605/4885 |
| US-20150291592-A1 | HEPATITIS C INHIBITOR COMPOUNDS | HAVCR2, CD4, HAX1 | LMNA 1423/4885MAPT 4556/4885ALDH1A1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.